Objective: Platelet-derived endothelial cell growth factor (PD-ECGF)/thymidine phosphorylase (TP) has been implicated in cancer angiogenesis, which is critical for tumor growth and metastasis. We investigated the relationship between the tissue concentration of PD-ECGF/TP and the clinicopathologic status in human lung cancer. Methods: The concentrations of PD-ECGF/TP in the tumor extracts of 139 primary human lung carcinomas were measured by using a highly specific and sensitive enzyme-linked immunosorbent assay. Key words: enzyme-linked immunosorbent assay; non-small cell lung cancer; platelet-derived endothelial cell growth factor; small cell lung cancer; thymidine phosphorylase Abbreviations: ELISA ϭ enzyme-linked immunosorbent assay; MoAb ϭ monoclonal antibody; NSCLC ϭ non-small cell lung cancer; PBS ϭ phosphate-buffered saline; PD-ECGF ϭ platelet-derived endothelial cell growth factor; pTNM ϭ pathologic TNM; SCLC ϭ small cell lung cancer; TP ϭ thymidine phosphorylase
M
etastasis is a multistep process in which tumor cells gain access to the vasculature in the primary tumor, survive in the circulation, arrest in the microvasculature of the target organ, exit from this microvasculature, and proliferate in the target tissues. Tumor angiogenesis plays a critical role in this process. Experimental and clinical evidence indicates that tumor growth and metastasis are dependent on angiogenesis [1] [2] [3] and that extensive angiogenesis has been shown to correlate with a worse prognosis in patients with various malignancies. 4 -7 Metastasis is more likely to spread from highly vascularized tumors because abundant new leaky vessels allow tumor cells more ready access to the circulation. 8, 9 Tumor cells are rarely shed into the circulation before the primary tumor is vascularized, [1] [2] [3] and micrometastases cannot grow to a detectable size until after they have become vascularized. 9 Thus, angiogenesis is necessary at the beginning as well as at the end of the metastatic cascade. A number of factors that stimulate angiogenesis have been identified, one of which is platelet-derived endothelial cell growth factor (PD-ECGF).
PD-ECGF was initially identified as a novel angiogenic factor present in platelets. 10, 11 Subsequent studies showed that PD-ECGF is identical to thymidine phosphorylase (TP), which catalyzes the reversible breakdown of thymidine to thymine in the presence of inorganic orthophosphate. PD-ECGF/TP differs from many endothelial mitogens in that it lacks both heparin-binding domains and a secretion peptide. The mechanism of its angiogenic action is still unclear; however, we know that the angiogenic action is dependent on its enzymatic activity. 12 PD-ECGF/TP is chemotactic for endothelial cells. 13 Hydrolysis of thymidine by PD-ECGF/TP gives rise to 2-deoxyribose 6-phosphate, which is readily dephosphorylated to 2-deoxyribose. The latter has been reported to be angiogenic. 14 Both mRNA and the protein expression of PD-ECGF/TP have been detected in human transformed cell lines, and active enzyme has been detected in their conditioned media. 15 The transfection of PD-ECGF/TP into transformed fibroblasts in nude mice resulted in increased tumor vascularity. 11 In addition, the transfection of PD-ECGF/TP into breast carcinoma cells promoted cancer cell growth in vivo. 13 The increased expression of PD-ECGF/TP correlated with the degree of malignancy in a variety of solid cancers, including breast cancer, 16, 17 ovarian cancer, 18 bladder cancer, 19 -21 gastric cancer, 22 and colon cancer, 23, 24 suggesting that PD-ECGF/TP might play an important role in the growth of these cancers. Very recently, Koukourakis et al 25 reported that the elevated expression of immunohistochemically identified PD-ECGF/TP in tumor cells is associated with more extensive angiogenesis and a poorer prognosis of non-small cell lung cancer (NSCLC). These observations prompted us to investigate the relationship between the tissue concentration of PD-ECGF/TP and the clinicopathologic status in human lung cancer by using a recently developed enzyme-linked immunosorbent assay (ELISA), which is a highly specific and sensitive sandwich method used to measure human PD-ECGF/TP concentrations. 26 We have found that tissue extracts from small cell lung cancer (SCLC) contain significantly lower PD-ECGF/TP concentrations than those contained in the tissue extracts from NSCLC.
Materials and Methods

Lung Tumors
Tumor specimens from 122 patients with NSCLC (73 adenocarcinomas and 49 squamous cell carcinomas) and 17 patients with SCLC were examined. The histologic classification was determined according to the criteria of the World Health Organization histologic typing of lung tumors. 27 When SCLC was suspected, immunostaining with chromogranins A was performed to confirm the diagnosis. To rule out potential mesotheliomas, hyaluronidase digestion followed by Alcian blue staining was performed. Bronchioloalveolar carcinomas and adenosquamous carcinomas were excluded from this study. The pathologic TNM (pTNM) stage was determined according to the newly revised classification of the American Joint Committee on Cancer and the Union Internationale Contre le Cancer. 28 None of the 122 patients with NSCLC, including the patients with clinical stage IIIA NSCLC, received preoperative chemotherapy or radiation therapy. In 17 patients with SCLC, 3 patients with limited disease and 1 patient with extensive disease received two or three cycles of chemotherapy before tumor specimens were obtained; chemotherapy consisted of cisplatin, doxorubicin, and etoposide.
The routine follow-up of these patients after surgery consisted of clinical evaluation every 2 months for the first 2 years and every 4 months thereafter. Disease recurrence was documented by physical examination, radiological and laboratory tests, and/or other relevant diagnostic procedures. The median follow-up period for 122 patients with NSCLC and for 17 patients with SCLC was 6.3 years (range, 1.5 to 8.8 years) and 6.1 years (range, 2.2 to 8.4 years), respectively.
Assay for PD-ECGF/TP
The tissue extracts were prepared as previously reported. 29 Briefly, a frozen tissue sample from each tumor (about 0.1 g) was quickly thawed at room temperature and then minced and rinsed with an ice-cold 3 mM Tris-HCl buffer, pH 7.5, containing 250 mM sucrose. The minced pieces were suspended in 1 mL of an ice-cold solution containing 3 mM Tris-HCl buffer, pH 7.5, and 250 mM sucrose, followed by homogenization in an ice bath, using a glass homogenizer (ANEX 30420; Teraoka Co Ltd; Osaka, Japan). The homogenate was further homogenized with an ultrasonic homogenizer (USH-20Z20S; Tokyo Rikakikai Co Ltd; Tokyo, Japan) for 2 min at 5°C and centrifuged at 3,000 rotations per minute for 20 min at 5°C. The concentration of PD-ECGF/TP in the resulting supernatant was assayed using an ELISA.
The assay is a sandwich method which has been recently developed. 26 Human PD-ECGF/TP was purified 525-fold from HCT116 human colon cancer xenografts (American Type Culture Collection; Rockville, MD) grown in BALB/c nu/nu mice. Mice were immunized with purified PD-ECGF/TP for the preparation of a monoclonal antibody (MoAb) to this enzyme. Six hybridomas producing anti-PD-ECGF/TP MoAbs, which were detected by Western blot analysis, were prepared from the spleen cells of the immunized mice. The isotypes of these hybridomas and their corresponding MoAbs were IgM, (104B) and IgG1, (232-2, 654 -1, 322E, 49 -4, and 204 -1). A sandwich ELISA for human PD-ECGF/TP was developed with MoAbs 104B and 232-2. This ELISA is sensitive enough to measure human PD-ECGF/TP levels, even in tumor tissue samples weighing as little as 10 mg. 26 A 96-well microtiter plate (Nunc-immunoplate Maxisorp; Nunc; Roskilde, Denmark) was incubated at 4°C overnight with 10 g/mL of the MoAb 104B in 10 mM phosphate-buffered saline (PBS) solution (pH 7.6). The plate was coated with the antibody and then incubated with 3% (w/v) nonfat dried milk in PBS (blocking buffer) for 1 h at room temperature. The plate was washed with PBS containing 0.05% polysorbate 20 and 0.05% sodium azide and then kept at 4°C until it was used. The tissue samples and standard solutions of PD-ECGF/TP were dispensed into a plate coated with the antibody. The plate was next incubated at 37°C for 1 h and then washed with 0.05% polysorbate 20 in PBS (washing buffer). After three washes, the plate was incubated with PD-ECGF/TP MoAb 232-2 at 1 g/mL in a blocking buffer for 1 h at 37°C and then washed. Finally, the plate was incubated with 2,000-fold diluted anti-mouse IgG1 conjugated with horseradish peroxidase (Bio-Rad; Hercules, CA) for 30 min at 37°C, washed three times with washing buffer, and developed with a substrate solution containing 3,3Ј,5,5Ј-tetramethyl benzidine and H 2 O 2 (TMB microwell peroxidase substrate system; Kirkegaard and Perry Laboratories; Gaithersburg, MD) for 10 to 20 min at room temperature. The peroxidase reaction was stopped by the addition of a 1 mol/L phosphate solution, and the amount of PD-ECGF/TP sandwiched between the two anti-PD-ECGF/TP MoAbs was estimated by measuring the absorbance at 450 nm with a plate reader (model 3550; Bio-Rad). The amount of PD-ECGF/TP was calibrated using standard solutions. One unit was defined as the amount of PD-ECGF/TP able to convert 1 M 5Ј-deoxy-5-fluorouridine to 5-fluorouracil in 1 h at 37°C (pH 7.4). The dose-response curve covered the range of 4.0 to 80 U/mL protein. When the activity in a sample was greater than the upper limit of the standard curve, the sample was diluted in a dilution buffer and assayed again. The PD-ECGF/TP concentration in each extract was expressed as U/mg protein. The protein concentration was determined by using the method of Lowry et al, 30 with bovine serum albumin as a standard.
To determine the reproducibility of the assay, five tissue samples were selected, and each sample was assayed five times. The coefficient of variation of the SD was within 1.4 to 8.9%.
Statistics
Data are expressed as the mean (Ϯ SD). The statistical significance of the differences in the PD-ECGF/TP concentrations was tested by using the Kruskal-Wallis test. The correlation of various disease parameters was analyzed by using the 2 test or the Fisher's Exact Test. The significance of the differences in the survival rates between the patient groups was calculated by using the log-rank test. Results were considered statistically significant when p Ͻ 0.05.
Results
Using a recently developed ELISA, PD-ECGF/TP was detected in extracts from 137 of 139 tumor specimens at concentrations that ranged from 2.0 to 169.5 U/mg protein. We measured PD-ECGF/TP concentrations in noncancerous tissue samples from three patients with NSCLC and used them as controls. Only 1 of the 3 noncancerous tissues showed detectable levels of PD-ECGF/TP concentration (4.1 U/mg protein). Figure 1 shows the distribution of the PD-ECGF/TP concentrations in 139 patients with lung cancer in terms of their histologic type. The mean (Ϯ SD) PD-ECGF/TP concentrations in patients with adenocarcinoma (n ϭ 73) and squamous cell carcinoma (n ϭ 49) were 30.7 Ϯ 22.9 U/mg protein (range, 7.6 to 169.5 U/mg protein; median value ϭ 25.2) and 32.0 Ϯ 19.8 U/mg protein (range, 8.0 to 84.4 U/mg protein; median value ϭ 25.4), respectively. No significant difference was found in the PD-ECGF/TP concentration between these two types of NSCLC. When the PD-ECGF/TP concentrations in the 73 adenocarcinomas and the 49 squamous cell carcinomas were compared with respect to the patients' gender, age, smoking history, and pTNM stage, no significant association was found between the PD-ECGF/TP concentration and any of these features (Table 1) . To evaluate the prognostic significance of PD-ECGF/TP concentration in tumor extracts measured by the ELISA, we attempted to determine a cut-off value that yielded a statistically significant separation between a low and high risk of death by using the method of Tandon et al. 31 However, there was no significant cut-off value that gave an optimal separation between low and high risk of death in the 122 patients with NSCLC (Fig 2) . Similarly, with respect to disease-free survival, there was no significant cut-off value that gave an optimal separation between a low and high risk of recurrence in the 122 patients with NSCLC.
As shown in Figure 1 , a Ͼ 8-fold lower mean concentration of PD-ECGF/TP was found in tissue extracts from SCLC (3.65 Ϯ 2.01 U/mg protein, ranging from undetectable to 6.1 U/mg protein; median value ϭ 4.5; n ϭ 17) than in those from adenocarcinomas (p ϭ 0.00005) or squamous cell carcinomas (p Ͻ 0.00001). No significant associations were found between the PD-ECGF/TP concentration and gender, age, smoking history, or extent of disease in SCLC patients ( Table 2) .
Discussion
PD-ECGF/TP is a protein that is involved with a wide range of activities, including angiogenesis, 13, 14 stimulation of DNA synthesis, 32 and endothelial cell migration. 13 Because the development of new blood vessels is essential for the growth and metastasis of solid tumors, this enzyme may play an important role in tumor progression. Several investigators have demonstrated that the increased expression of PD-ECGF/TP correlated with the degree of malignancy in a variety of solid cancers. 16 -24 However, the data presented in this paper suggest that the reduced expression of PD-ECGF/TP does not necessarily indicate a less aggressive tumor, because rapid growth and dissemination is the hallmark of SCLC. On the other hand, increased PD-ECGF/TP expression may permit, but does not guarantee, progressive tumor spread. For example, pulmonary carcinoid tumors are highly vascular and contain relatively high PD-ECGF/TP concentrations (unpublished data), but rarely metastasize to distant sites. Because of the complex nature of cancer spread, it is unlikely that any single factor is solely responsible for the growth and metastasis of a particular tumor type. The extent of angiogenesis and inflammatory response is similar in NSCLC and SCLC. 33, 34 Thus, the striking difference in PD-ECGF/TP concentrations between NSCLC and SCLC is intriguing, because it suggests that alternative pathways for angiogenesis are used by these cancers. Other angiogenic factors, such as fibroblast growth factor and vascular endothelial growth factor, may be responsible for the neovascularization in SCLC. Our finding that tissue extracts from SCLC contain significantly lower PD-ECGF/TP concentrations than those from NSCLC is consistent with the findings of two previous studies. 34, 35 Heldin et al 35 reported that cell lines, which were derived from a squamous cell carcinoma and two adenocarcinomas, expressed PD-ECGF/TP mRNA and that protein levels were detectable when immunoblotting was performed and TP activity in the cell lysates and conditioned media were examined. In contrast, none of the four SCLC cell lines had detectable PD-ECGF/TP messenger RNA or the corresponding protein. Furthermore, Giatromanolaki et al 34 recently evaluated the immunohistochemical expression of PD-ECGF/TP in human lung cancer tissues using the P-GF0.44C MoAb and demonstrated that positive staining in Ͼ 50% of the cells was observed in 16 of 38 adenocarcinomas (42%), in 23 of 71 squamous cell carcinomas (32%), and in 0 of 22 small cell carcinomas (0%). It is unclear whether the down-regulation of PD-ECGF/TP in SCLC is merely an epiphenomenon or whether it is important for tumor progression or survival in this type of lung cancer. Furthermore, whether this finding may ultimately be exploited to distinguish two entities of lung cancer remains to be investigated. The clinical application of this finding, particularly as a preoperative marker for SCLC, should be addressed because a local treatment modality, such as surgical resection, is likely to have little impact on the prognosis of patients with SCLC. 36 Recently, Koukourakis et al 25 demonstrated that the elevated expression of immunohistochemically identified PD-ECGF/TP in tumor cells, which is caused by the P-GF0.44C MoAb, was associated with a poorer prognosis in 107 patients with NSCLC. However, our study failed to find any prognostic value of the tissue concentration of PD-ECGF/TP in 122 patients with NSCLC, regardless of the cut-off value chosen. The discrepancy between the immunohistochemical and biochemical studies may have several explanations. The antibodies used in the cytosol assay and the immunohistochemical study may differ in their sensitivity and specificity. In addition, the contribution by macrophages, leukocytes, and other stromal cells to the total cytosol PD-ECGF/TP concentration is unavoidable in the biochemical assay. Lung tumors are heterogeneous, with varying tumor cellularity, amounts of stroma, and infiltration by macrophages, lymphocytes, neutrophils, and fibroblasts. It is possible that some of the protein biochemically detected in the tumor cytosols was extracted from the infiltrating inflammatory cells. Indeed, immunohistochemical staining of PD-ECGF/TP was not limited to the tumor cells; it was also observed in these inflammatory cells. 25, 37 Very recently, Koukourakis et al 38 demonstrated that stromal macrophage and fibroblast PD-ECGF/TP reactivity may have an important role in NSCLC behavior. Therefore, it is possible that high PD-ECGF/TP levels determined in whole tumor extracts primarily reflect inflammatory cell involvement in the tumor rather than in the tumor cells themselves. Hence, although the intensity and extent of PD-ECGF/TP staining of cancer cells may be significant in predicting a poorer prognosis in patients with NSCLC, no such prognostic value can be demonstrated by the biochemical method. In addition, this study does not take into account the influence of other known prognostic factors, such as stage, histologic grade, and performance status in the survival analysis.
The tissue concentration of PD-ECGF/TP in 122 patients with NSCLC varied over a wide range, and some NSCLC samples had low PD-ECGF/TP concentrations. However, the present study failed to find any specific characteristics in such patients. Future follow-up studies should be done to examine whether the patients with low PD-ECGF/TP concentrations showed any specific characteristics.
In conclusion, this study demonstrates for the first time the differential concentration of PD-ECGF/TP in NSCLC and SCLC. These data, together with other data on PD-ECGF/TP expression in human lung carcinoma cell lines 34 and the immunohistochemical expression of PD-ECGF/TP in lung cancer tissues, 35 suggest that these two types of lung cancer use alternative pathways for angiogenesis. Inhibitors of PD-ECGF/TP have recently been developed, and they are under laboratory investigation to determine their effectiveness as treatments for various types of cancer. 12 However, the present study suggests that these inhibitors may not be effective against SCLC.
